New Drug Delivery Systems Are Transforming How We Treat Retinal Disease
From refillable eye implants to suprachoroidal injections, next-gen delivery platforms are slashing treatment burden for AMD and diabetic eye disease.
Summary
Retinal diseases like age-related macular degeneration and diabetic macular edema require frequent intravitreal injections that burden patients and healthcare systems. This comprehensive review examines FDA-approved and late-stage delivery innovations designed to reduce injection frequency and improve outcomes. Key platforms covered include the ranibizumab port delivery system (Susvimo), biodegradable and non-biodegradable polymer implants, tyrosine kinase inhibitor implants like OTX-TKI (Axpaxli) and EYP-1901 (Duravyu), bispecific antibodies, suprachoroidal and subretinal delivery routes, topical high-concentration formulations, encapsulated cell therapy, and gene therapy vectors. Each approach targets the core limitation of conventional injections: short drug half-life combined with chronic disease requiring lifelong treatment.
Detailed Summary
Intravitreal injections of anti-VEGF agents are the current standard of care for retinal diseases including neovascular AMD, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. However, drugs like ranibizumab, aflibercept, and bevacizumab have intraocular half-lives of roughly 7–9 days, necessitating monthly or bimonthly injections. Real-world studies show that patients receiving fewer than six injections per year experience significantly worse visual outcomes compared to those on fixed, high-frequency regimens. This treatment burden drives poor adherence and suboptimal outcomes, underscoring urgent demand for durable, lower-frequency delivery solutions.
The ranibizumab port delivery system (PDS, Susvimo) represents a landmark step forward. This surgically implanted, refillable intravitreal reservoir releases ranibizumab continuously at an estimated half-life of ~106 days, with refills required only every 24 weeks. Phase 3 trials (Archway for nAMD, Pagoda for DME, Pavilion for DR) confirmed non-inferiority to monthly ranibizumab, with ~95–98% of participants requiring no supplemental injections. FDA-approved for nAMD in 2021 and DME subsequently, the device carries a black-box warning for elevated endophthalmitis risk and underwent a voluntary recall in 2022 for septum dislodgement before being redesigned and relaunched.
Polymer-based and implantable small-molecule platforms offer another route. OTX-TKI (Axpaxli, axitinib implant) is a PLGA-based intravitreal implant delivering the tyrosine kinase inhibitor axitinib, targeting VEGFR1–3 and PDGFR. Phase 2 data showed durability up to 9 months in nAMD patients. EYP-1901 (Duravyu, vorolanib implant) uses the Durasert sustained-release platform to deliver a tyrosine kinase inhibitor intravitreally with a target 6-month dosing interval. KSI-301 (tarcocimab tedromer) is a biopolymer-conjugated anti-VEGF antibody designed for extended durability, while KSI-501 adds IL-6 pathway inhibition for a dual-mechanism approach. These platforms aim to dramatically extend dosing intervals beyond what current protein biologics allow.
Alternative anatomical routes are also advancing. Suprachoroidal delivery (e.g., Xipere, triamcinolone acetonide for uveitic macular edema) enables targeted posterior segment drug delivery with reduced anterior segment side effects. Subretinal delivery is central to gene therapy approaches such as ABBV-RGX-314, which uses an AAV8 vector to express anti-VEGF protein, and revakinagene taroretcel-lwey (Encelto/NT-501), an encapsulated cell therapy implant secreting CNTF for geographic atrophy. Topical delivery innovations include OCS-01, a high-concentration dexamethasone nanoemulsion for DME, representing a non-invasive alternative. AU-011 (belzupacap sarotalocan) represents targeted viral-like particle delivery for uveal melanoma. Subcutaneous and systemic approaches such as elamipretide and 4D-150 (a dual-targeting intravitreal gene therapy against VEGF and VEGF-C) round out the landscape.
Despite remarkable progress, challenges persist. Surgical risks with implantable devices, immune responses to viral vectors, difficulty penetrating the blood-retinal barrier for topical/systemic agents, and the need for precise, personalized dosing remain significant hurdles. The authors emphasize that interdisciplinary collaboration combining materials science, pharmacokinetics, genomics, and clinical ophthalmology will be essential to realize the full potential of these delivery innovations.
Key Findings
- The ranibizumab port delivery system reduced injection frequency to every 24 weeks with ~95–98% of patients needing no supplemental injections.
- Polymer-based TKI implants (OTX-TKI, EYP-1901) demonstrated nAMD durability up to 6–9 months in early-phase trials.
- Suprachoroidal triamcinolone (Xipere) enables targeted posterior delivery with reduced anterior segment steroid side effects.
- Gene therapy vectors like ABBV-RGX-314 aim for one-time subretinal treatment replacing chronic anti-VEGF injection regimens.
- Topical OCS-01 dexamethasone nanoemulsion shows potential as a non-invasive alternative for DME management.
Methodology
This is a structured narrative review focusing on FDA-approved retinal drug delivery systems from the past five years and therapies currently in Phase 3 clinical development. The authors synthesized data from pivotal Phase 2 and Phase 3 clinical trials, real-world studies, and pharmacokinetic analyses. No meta-analysis or systematic search protocol was reported.
Study Limitations
As a narrative review, the paper does not employ systematic search methodology, introducing potential selection bias in evidence presented. Many highlighted therapies remain in Phase 2–3 trials with limited long-term safety and durability data. Real-world performance of novel delivery systems may differ from controlled trial results, and cost-effectiveness analyses are largely absent.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.